Charles N Landen Selected Research

1,2-oleoylphosphatidylcholine (DOPC)

5/2014	EDD enhances cell survival and cisplatin resistance and is a therapeutic target for epithelial ovarian cancer.
11/2011	Silencing of p130cas in ovarian carcinoma: a novel mechanism for tumor cell death.
6/2009	Dual targeting of EphA2 and FAK in ovarian carcinoma.
3/2008	Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth.
12/2006	Intraperitoneal delivery of liposomal siRNA for therapy of advanced ovarian cancer.
8/2006	Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy.
8/2005	Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Charles N Landen Research Topics

Disease

63	Neoplasms (Cancer) 01/2022 - 05/2003
57	Ovarian Neoplasms (Ovarian Cancer) 10/2021 - 12/2004
19	Carcinoma (Carcinomatosis) 05/2019 - 02/2006
10	Ovarian Epithelial Carcinoma 11/2017 - 02/2006
4	Neoplasm Metastasis (Metastasis) 01/2022 - 03/2006
4	Ascites 01/2019 - 03/2006
3	Carcinogenesis 01/2016 - 08/2004
2	Endometrial Neoplasms (Endometrial Cancer) 12/2010 - 12/2007
2	Necrosis 10/2007 - 10/2006
2	Genomic Instability 07/2007 - 12/2004
1	Bites and Stings (Sting) 10/2021
1	Hypoxia (Hypoxemia) 01/2019

Drug/Important Bio-Agent (IBA)

12	Small Interfering RNA (siRNA)IBA 05/2019 - 08/2005
12	Docetaxel (Taxotere)FDA Link 11/2011 - 12/2005
11	Paclitaxel (Taxol)FDA LinkGeneric 11/2019 - 08/2005
11	PlatinumIBA 01/2019 - 08/2006
11	taxaneIBA 08/2014 - 12/2005
8	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 12/2010 - 08/2006
7	Cisplatin (Platino)FDA LinkGeneric 01/2021 - 02/2012
7	Proteins (Proteins, Gene)FDA Link 01/2021 - 11/2006
7	1,2-oleoylphosphatidylcholine (DOPC)IBA 05/2014 - 08/2005
7	Biological ProductsIBA 12/2013 - 12/2007
6	Carboplatin (JM8)FDA LinkGeneric 01/2022 - 01/2008
6	Monoclonal AntibodiesIBA 01/2021 - 10/2006
6	Liposomes (Liposome)IBA 05/2019 - 08/2005
6	Proliferating Cell Nuclear Antigen (PCNA)IBA 11/2011 - 09/2006
5	Matrix Metalloproteinases (MMPs)IBA 01/2021 - 01/2006
4	DNA (Deoxyribonucleic Acid)IBA 10/2021 - 10/2006
4	Pharmaceutical PreparationsIBA 01/2021 - 07/2014
4	Bevacizumab (Avastin)FDA Link 10/2019 - 12/2007
3	Focal Adhesion Protein-Tyrosine KinasesIBA 05/2019 - 12/2005
3	Niclosamide FDA Link 10/2018 - 07/2014
3	CateninsIBA 10/2018 - 07/2014
3	Cell-Free Nucleic AcidsIBA 01/2018 - 10/2006
3	AEE 788 (AEE788)IBA 07/2007 - 10/2006
3	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 11/2006 - 08/2004
2	AntibodiesIBA 11/2021 - 01/2018
2	CX 5461IBA 10/2021 - 11/2017
2	Phosphoric Monoester Hydrolases (Phosphatases)IBA 01/2021 - 02/2018
2	JMS-053IBA 01/2021 - 02/2018
2	Transcription Factors (Transcription Factor)IBA 01/2019 - 01/2016
2	Oncogene Proteins (Oncogene Protein)IBA 02/2018 - 11/2006
2	Death Domain ReceptorsIBA 01/2018 - 03/2012
2	sonidegibIBA 08/2014 - 07/2012
2	Proteasome InhibitorsIBA 08/2014 - 01/2008
2	Bortezomib (Velcade)FDA Link 08/2014 - 01/2008
2	Caspase 3 (Caspase-3)IBA 04/2013 - 12/2005
2	sulforaphaneIBA 03/2013 - 01/2013
2	epigallocatechin gallate (epigallocatechin-3-gallate)IBA 03/2013 - 01/2013
2	TeaIBA 03/2013 - 01/2013
2	EndoglinIBA 01/2013 - 02/2012
2	CytokinesIBA 02/2012 - 03/2008
2	DNA Nucleotidylexotransferase (Terminal Deoxynucleotidyl Transferase)IBA 11/2011 - 11/2006
2	LigandsIBA 09/2011 - 04/2008
2	EnzymesIBA 12/2010 - 02/2006
2	Integrin alphaVbeta3IBA 12/2009 - 11/2008
2	etaracizumabIBA 12/2009 - 11/2008
2	Integrin beta3 (GPIIIa)IBA 12/2009 - 11/2008
2	Epinephrine (Adrenaline)FDA LinkGeneric 11/2007 - 01/2006
2	Isoproterenol (Isoprenaline)FDA LinkGeneric 11/2007 - 01/2006
2	Norepinephrine (Noradrenaline)FDA LinkGeneric 11/2007 - 01/2006
2	Adrenergic Receptors (Adrenergic Receptor)IBA 11/2007 - 08/2006
2	Cyclic AMP-Dependent Protein Kinases (cAMP-Dependent Protein Kinase)IBA 11/2007 - 08/2006
2	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 07/2007 - 01/2007
2	Matrix Metalloproteinase 14 (MT1-MMP)IBA 01/2007 - 03/2006
1	Drug CombinationsIBA 10/2021
1	InterferonsIBA 10/2021
1	Interferon Type IIBA 10/2021
1	PlectinIBA 01/2021
1	Arsenic Trioxide (Trisenox)FDA Link 11/2019
1	Arsenicals (Arsenic Compounds)IBA 11/2019
1	Glucose (Dextrose)FDA LinkGeneric 01/2019
1	SphingosineIBA 11/2018
1	CeramidesIBA 11/2018
1	LipidsIBA 11/2018
1	Tamoxifen FDA LinkGeneric 11/2018
1	Selective Estrogen Receptor Modulators (SERM)IBA 11/2018
1	Fingolimod Hydrochloride (FTY720)FDA Link 11/2018
1	Protein Tyrosine PhosphatasesIBA 02/2018
1	RNA Polymerase I (Polymerase I, RNA)IBA 11/2017
1	Member 1 Subfamily B ATP Binding Cassette TransporterIBA 10/2017
1	salicylamideIBA 12/2016
1	Anti-Bacterial Agents (Antibiotics)IBA 11/2016
1	GlycosyltransferasesIBA 01/2016
1	Gemcitabine FDA Link 01/2016
1	Sialic AcidsIBA 01/2016
1	Glycoproteins (Glycoprotein)IBA 01/2016
1	RNA (Ribonucleic Acid)IBA 09/2014
1	Proteasome Endopeptidase Complex (Proteasome)IBA 08/2014
1	Gamma Secretase Inhibitors and ModulatorsIBA 08/2014
1	UbiquitinIBA 08/2014
1	Poly(ADP-ribose) Polymerase InhibitorsIBA 08/2014
1	veliparibIBA 08/2014

Therapy/Procedure

32	Therapeutics 01/2022 - 08/2005
17	Drug Therapy (Chemotherapy) 01/2022 - 10/2006
3	Aftercare (After-Treatment) 01/2022 - 12/2005
2	Immunotherapy 10/2021 - 01/2014
1	Salpingo-oophorectomy 01/2020
1	Neoadjuvant Therapy 01/2018
1	Menstrual Hygiene Products (Menstrual Pad) 11/2014